Dyslipidemia Associated with Chronic Kidney Disease
Vasilis Tsimihodimos, Zoi Mitrogianni, Moses Elisaf*
Identifiers and Pagination:Year: 2011
First Page: 41
Last Page: 48
Publisher Id: TOCMJ-5-41
Article History:Received Date: 9/12/2010
Revision Received Date: 6/1/2011
Acceptance Date: 6/1/2011
Electronic publication date: 24/2/2011
Collection year: 2011
open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
Cardiovascular disease is a major cause of morbidity and mortality in patients with impaired renal function. Dyslipidemia has been established as a well-known traditional risk factor for cardiovascular disease (CVD) in the general population and it is well known that patients with chronic kidney disease (CKD) exhibit significant alterations in lipoprotein metabolism. In this review, the pathogenesis and treatment of CKD-induced dyslipidemia are discussed. Studies on lipid abnormalities in predialysis, hemodialysis and peritoneal dialysis patients are analyzed. In addition, the results of the studies that tested the effects of the hypolipidemic drugs on cardiovascular morbidity and mortality in patients with CKD are reported.